Ribonucleoprotein HNRNPA2B1 Interacts with and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells

Gastroenterology

Volumn 147, Issue 4, 2014, Pages 882-892.e8

  Barceló, Carles ^a   Etchin, Julia ^b   Mansour, Marc R ^b   Sanda, Takaomi ^b,c   Ginesta, Mireia M ^d   Sanchez Arévalo Lobo, Victor J ^e   Real, Francisco X ^e   Capellà, Gabriel ^d   Estanyol, Josep M ^a   Jaumot, Montserrat ^a   Look, A Thomas ^b   Agell, Neus ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Carcinogenesis; Model; Mouse; Oncogene; Signal; Transduction

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2B1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; PROTEIN KINASE B; PROTEIN S6; PROTEIN TAG; REGULATOR PROTEIN; SERINE; SHORT HAIRPIN RNA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; HNRNP A2; KRAS PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN BINDING; RAS PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; FEMALE; GENE ACTIVATION; GENE INTERACTION; GENE SILENCING; HELA CELL LINE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RNA PROCESSING; SIGNAL TRANSDUCTION; ANIMAL; CELL ADHESION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TIME; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; MICE; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921656525     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.06.041     Document Type: Article

References (70)

1. M. Malumbres, and M. Barbacid RAS oncogenes: the first 30 years Nat Rev Cancer 3 2003 459 465
2. J. Downward Control of ras activation Cancer Surv 27 1996 87 100
3. J.L. Bos ras oncogenes in human cancer: a review Cancer Res 49 1989 4682 4689
4. I.A. Prior, P.D. Lewis, and C. Mattos A comprehensive survey of Ras mutations in cancer Cancer Res 72 2012 2457 2467
5. S. Schubbert, K. Shannon, and G. Bollag Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 2007 295 308
6. A.J. Aguirre, N. Bardeesy, and M. Sinha Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma Genes Dev 17 2003 3112 3126
7. K.M. Haigis, K.R. Kendall, and Y. Wang Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon Nat Genet 40 2008 600 608
8. C.L. Johnson, J.M. Peat, and S.N. Volante Activation of protein kinase Cδ leads to increased pancreatic acinar cell dedifferentiation in the absence of MIST1 J Pathol 228 2012 351 365
9. J.M. Shields, K. Pruitt, and A. McFall Understanding Ras: "it ain"t over "til it"s over.' Trends Cell Biol 10 2000 147 154
10. C.J. Marshall Ras effectors Curr Opin Cell Biol 8 1996 197 204
11. R. Shalom-Feuerstein, S.J. Plowman, and B. Rotblat K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3 Cancer Res 68 2008 6608 6616
12. P. Villalonga, C. López-Alcalá, and M. Bosch Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling Mol Cell Biol 21 2001 7345 7354
13. G. Zimmermann, B. Papke, and S. Ismail Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling Nature 497 2013 638 642
14. A. Chandra, H.E. Grecco, and V. Pisupati The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins Nat Cell Biol 14 2012 148 258
15. K.L. Inder, C. Lau, and D. Loo Nucleophosmin and nucleolin regulate K-Ras plasma membrane interactions and MAPK signal transduction J Biol Chem 284 2009 28410 28419
16. J. Settleman Oncogene addiction Curr Biol 22 2012 R43 R44
17. I.B. Weinstein, and A. Joe Oncogene addiction Cancer Res 68 2008 3077 3080 discussion 3080
18. E.A. Collisson, A. Sadanandam, and P. Olson Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy Nat Med 17 2011 500 503
19. M.A. Collins, F. Bednar, and Y. Zhang Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice J Clin Invest 122 2012 639 653
20. M.A. Collins, J.-C. Brisset, and Y. Zhang Metastatic pancreatic cancer is dependent on oncogenic Kras in mice PLoS One 7 2012 e49707
21. E.L. Jackson, N. Willis, and K. Mercer Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras Genes Dev 15 2001 3243 3248
22. K.L. Bryant, J.D. Mancias, and A.C. Kimmelman KRAS: feeding pancreatic cancer proliferation Trends Biochem Sci 39 2014 91 100
23. G.H. Fisher, S.L. Wellen, and D. Klimstra Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes Genes Dev 15 2001 3249 3262
24. N. Sunaga, D.S. Shames, and L. Girard Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy Mol Cancer Ther 10 2011 336 346
25. L. Chin, A. Tam, and J. Pomerantz Essential role for oncogenic Ras in tumour maintenance Nature 400 1999 468 472
26. A. Vincent, J. Herman, and R. Schulick Pancreatic cancer Lancet 378 2011 607 620
27. M. Carpelan-Holmström, S. Nordling, and E. Pukkala Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry Gut 54 2005 385 387
28. Y. Pylayeva-Gupta, K.E. Lee, and C.H. Hajdu Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia Cancer Cell 21 2012 836 847
29. S.R. Hingorani, E.F. Petricoin, and A. Maitra Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse Cancer Cell 4 2003 437 450
30. J.P. Morris, S.C. Wang, and M. Hebrok KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma Nat Rev Cancer 10 2010 683 695
31. M. Hidalgo Pancreatic cancer N Engl J Med 362 2010 1605 1617
32. Y. Pylayeva-Gupta, E. Grabocka, and D. Bar-Sagi RAS oncogenes: weaving a tumorigenic web Nat Rev Cancer 11 2011 761 774
33. C. Guerra, A.J. Schuhmacher, and M. Cañamero Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice Cancer Cell 11 2007 291 302
34. A.V. Pinho, I. Rooman, and M. Reichert Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis Gut 60 2011 958 966
35. B. Seidler, A. Schmidt, and U. Mayr A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors Proc Natl Acad Sci U S A 105 2008 10137 10142
36. S. Eser, N. Reiff, and M. Messer Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer Cancer Cell 23 2013 406 420
37. C. Navas, I. Hernández-Porras, and A.J. Schuhmacher EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma Cancer Cell 22 2012 318 330
38. A. Singh, P. Greninger, and D. Rhodes A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival Cancer Cell 15 2009 489 500
39. Magliano MP di, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013;144:1220-1229.
40. J. Zhou, J.L. Mulshine, and E.J. Unsworth Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4 J Biol Chem 271 1996 10760 10766
41. M.S. Tockman, J.L. Mulshine, and S. Piantadosi Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression Clin Cancer Res 3 1997 2237 2246
42. H. Cui, F. Wu, and Y. Sun Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma BMC Cancer 10 2010 356
43. H. Mizuno, M. Honda, and T. Shirasaki Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma Liver Int 32 2012 1146 1155
44. Y. He, and R. Smith Nuclear functions of heterogeneous nuclear ribonucleoproteins A/B Cell Mol Life Sci 66 2009 1239 1256
45. S.P. Han, Y.H. Tang, and R. Smith Functional diversity of the hnRNPs: past, present and perspectives Biochem J 430 2010 379 392
46. L. Ferron, A. Davies, and K.M. Page The stargazin-related protein gamma 7 interacts with the mRNA-binding protein heterogeneous nuclear ribonucleoprotein A2 and regulates the stability of specific mRNAs, including CaV2.2 J Neurosci 28 2008 10604 10617
47. R. Golan-Gerstl, M. Cohen, and A. Shilo Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma Cancer Res 71 2011 4464 4472
48. S. Zhao, L. Cao, and J.W. Freeman Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines Oncogenesis 2 2013 e76
49. C. Agbunag, and D. Bar-Sagi Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells Cancer Res 64 2004 5659 5663
50. E.A. Collisson, C.L. Trejo, and J.M. Silva A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma Cancer Discov 2 2012 685 693
51. C.M. Ardito, B.M. Grüner, and K.K. Takeuchi EGF receptor is required for KRAS-induced pancreatic tumorigenesis Cancer Cell 22 2012 304 317
52. B. Alvarez-Moya, C. López-Alcalá, and M. Drosten K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function Oncogene 29 2010 5911 5922
53. C. Barceló, N. Paco, and A.J. Beckett Oncogenic K-ras segregates at spatially distinct plasma membrane signaling platforms according to its phosphorylation status J Cell Sci 126 2013 4553 4559
54. C. Barcelo, N. Paco, and M. Morell Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth Cancer Res 74 2014 1190 1199
55. N.L. Solimini, J. Luo, and S.J. Elledge Non-oncogene addiction and the stress phenotype of cancer cells Cell 130 2007 986 988
56. B. Carpenter, C. MacKay, and A. Alnabulsi The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression Biochim Biophys Acta 1765 2006 85 100
57. O. Bajenova, E. Stolper, and S. Gapon Surface expression of heterogeneous nuclear RNA binding protein M4 on Kupffer cell relates to its function as a carcinoembryonic antigen receptor Exp Cell Res 291 2003 228 241
58. A. Iervolino, G. Santilli, and R. Trotta hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis Mol Cell Biol 22 2002 2255 2266
59. X.R. Bustelo, K.L. Suen, and W.M. Michael Association of the vav proto-oncogene product with poly(rC)-specific RNA-binding proteins Mol Cell Biol 15 1995 1324 1332
60. I. Van Seuningen, J. Ostrowski, and X.R. Bustelo The K protein domain that recruits the interleukin 1-responsive K protein kinase lies adjacent to a cluster of c-Src and Vav SH3-binding sites. Implications that K protein acts as a docking platform J Biol Chem 270 1995 26976 26985
61. J. Vera, M. Jaumot, and J.M. Estanyol Heterogeneous nuclear ribonucleoprotein A2 is a SET-binding protein and a PP2A inhibitor Oncogene 25 2006 260 270
62. Y. Yan-Sanders, G.J. Hammons, and B.D. Lyn-Cook Increased expression of heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP) in pancreatic tissue from smokers and pancreatic tumor cells Cancer Lett 183 2002 215 220
63. W.-J. Gu, and H.-L. Liu Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA Anticancer Drugs 24 2013 566 576
64. A.V. Biankin, N. Waddell, and K.S. Kassahn Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes Nature 491 2012 399 405
65. Y. Samuels, L.A. Diaz, and O. Schmidt-Kittler Mutant PIK3CA promotes cell growth and invasion of human cancer cells Cancer Cell 7 2005 561 573
66. J.F. Hancock, A.I. Magee, and J.E. Childs All ras proteins are polyisoprenylated but only some are palmitoylated Cell 57 1989 1167 1177
67. R. Ballester, M.E. Furth, and O.M. Rosen Phorbol ester- and protein kinase C-mediated phosphorylation of the cellular Kirsten ras gene product J Biol Chem 262 1987 2688 2695
68. J.D. Evans, P.A. Cornford, and A. Dodson Expression patterns of protein kinase C isoenzymes are characteristically modulated in chronic pancreatitis and pancreatic cancer Am J Clin Pathol 119 2003 392 402
69. K. Taniuchi, K. Yokotani, and T. Saibara BART inhibits pancreatic cancer cell invasion by PKCα inactivation through binding to ANX7 PLoS One 7 2012 e35674
70. P. Jasinski, P. Zwolak, and K. Terai Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo Transl Res 152 2008 203 212